508 related articles for article (PubMed ID: 29061013)
1. [The development of biosimilars in oncology].
Jiang SY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):721-725. PubMed ID: 29061013
[TBL] [Abstract][Full Text] [Related]
2. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
[TBL] [Abstract][Full Text] [Related]
3. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
Serna-Gallegos TR; La-Fargue CJ; Tewari KS
Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
[TBL] [Abstract][Full Text] [Related]
4. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
5. The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab.
Giuliani J; Bonetti A
Anticancer Res; 2019 Jul; 39(7):3971-3973. PubMed ID: 31262930
[TBL] [Abstract][Full Text] [Related]
6. Introduction and commentary: Paving the way for biosimilars in oncology.
Abraham J
Semin Oncol; 2013 Dec; 40 Suppl 1():S1-4. PubMed ID: 24267943
[No Abstract] [Full Text] [Related]
7. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer.
Hara F; Tajima K; Tanabe K
Future Oncol; 2019 Apr; 15(12):1353-1361. PubMed ID: 30767568
[TBL] [Abstract][Full Text] [Related]
8. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
9. [Biosimilar drugs in oncology].
Levêque D
Bull Cancer; 2016 Mar; 103(3):294-8. PubMed ID: 26832422
[TBL] [Abstract][Full Text] [Related]
10. The evolution of biosimilars in oncology, with a focus on trastuzumab.
Nixon NA; Hannouf MB; Verma S
Curr Oncol; 2018 Jun; 25(Suppl 1):S171-S179. PubMed ID: 29910660
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars in oncology: Effects on economy and therapeutic innovations.
Hübel K; Kron F; Lux MP
Eur J Cancer; 2020 Nov; 139():10-19. PubMed ID: 32950935
[TBL] [Abstract][Full Text] [Related]
12. A clinician's guide to biosimilars in oncology.
Rugo HS; Linton KM; Cervi P; Rosenberg JA; Jacobs I
Cancer Treat Rev; 2016 May; 46():73-9. PubMed ID: 27135548
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
BioDrugs; 2019 Aug; 33(4):357-371. PubMed ID: 31175632
[TBL] [Abstract][Full Text] [Related]
14. A Clinical Review of Biosimilars Approved in Oncology.
Ngo D; Chen J
Ann Pharmacother; 2021 Mar; 55(3):362-377. PubMed ID: 32715722
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars in oncology: from development to clinical practice.
Rak Tkaczuk KH; Jacobs IA
Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
[TBL] [Abstract][Full Text] [Related]
16. Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies.
Safdar A; Butt MH; Ahmad A; Zaman M
J Oncol Pharm Pract; 2021 Jul; 27(5):1195-1204. PubMed ID: 34096401
[TBL] [Abstract][Full Text] [Related]
17. Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.
Lyman GH
J Oncol Pract; 2017 Sep; 13(9_suppl):7s-9s. PubMed ID: 28898591
[No Abstract] [Full Text] [Related]
18. Developing oncology biosimilars: an essential approach for the future.
Abraham J
Semin Oncol; 2013 Dec; 40 Suppl 1():S5-24. PubMed ID: 24267944
[TBL] [Abstract][Full Text] [Related]
19. Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China: A Systematic Review and Meta-Analysis.
Luo X; Du X; Li Z; Liu J; Lv X; Li H; Guo Q; Wang C; Xue X; Le K; Jiang X; Huang L; Yang Y
JAMA Netw Open; 2023 Oct; 6(10):e2337348. PubMed ID: 37824143
[TBL] [Abstract][Full Text] [Related]
20. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
Kim WS; Coiffier B; Kwon HC; Kim S
Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
